论文部分内容阅读
为探讨血管紧张素转换酶抑制剂(ACEI)依那普利(enalapril)和β选择性阻滞剂氨酰心安(atenolol)对非糖尿病性蛋白尿病人的抗高血压、肾血液动力学和抗蛋白尿作用,进行前瞻性双盲、随机的16周研究。病人和方法选择长期抗高血压治疗、肾功能进展性损害病人27例,其中慢性肾炎13例,慢性间质性肾炎或肾盂肾炎7例和肾硬化
To investigate the effects of enalapril, an ACE inhibitor, and atenolol, a beta-selective blocker, on antihypertensive, renal hemodynamics, and anti-nephrotoxicity in nondiabetic proteinuric patients Proteinuria, prospective, double-blind, randomized 16-week study. Patients and methods of choice for long-term antihypertensive treatment, progressive damage to renal function in 27 patients, including chronic nephritis in 13 cases, chronic interstitial nephritis or pyelonephritis in 7 cases and nephrosclerosis